Spectrum Pharmaceuticals Signs a Strategic Partnership With Servier Canada
January 11 2016 - 7:00AM
Business Wire
Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), a biotechnology
company with fully integrated commercial and drug development
operations and a primary focus in Hematology and Oncology and
Servier Canada Inc., an affiliate of Servier a research-oriented
pharmaceutical company which is pioneering new therapies primarily
for cancer and cardiovascular diseases, announce the signing of a
strategic partnership. As part of this partnership, Spectrum will
grant the exclusive rights to develop and commercialize in Canada a
franchise of four Spectrum hemato-oncology drugs: ZEVALIN®
(ibritumomab tiuxetan) Injection for intravenous use,
Folotyn®(pralatrexate injection), Beleodaq® (belinostat) for
Injection and Marqibo® (vinCRIStine sulfate LIPOSOME injection) for
intravenous infusion. Spectrum will receive $6 million in upfront
payments, plus development milestone payments and royalties based
on net product sales.
“We are pleased to announce this strategic partnership with
Servier, a leading company in Canada,” said Rajesh C. Shrotriya,
MD, Chairman and Chief Executive Officer of Spectrum
Pharmaceuticals. “This deal allows us to continue to focus on our
core priorities including SPI-2012, Poziotinib, Apaziquone and
Evomela™. This year we plan to initiate two key trials with drugs
that target blockbuster markets and we are looking forward to
hearing from the FDA on two of our NDA submissions. We believe that
our pipeline has never been as strong as it is today, and we
continue to focus on executing on our key priorities.”
“This strategic partnership between Spectrum Pharmaceuticals and
Servier Canada will contribute to consolidate our global strategy
in Oncology. Our ambition is to become a benchmark player in this
field,” said Frédéric Sesini, Executive Vice-President
International Operations of Groupe Servier. “We are fully committed
in providing Canadian patients with innovative treatment options.
With this key partnership, Servier Canada Oncology will start
operating and will work to make these treatments available soon,”
underlined Frederic Fasano, Chief Executive Officer of Servier
Canada Inc.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company
focused on acquiring, developing, and commercializing drug
products, with a primary focus in Hematology and Oncology. Spectrum
currently markets five hematology/oncology drugs, and expects an
FDA decision on another hematology drug in the first half of 2016.
Additionally, Spectrum's pipeline includes three drugs targeting
blockbuster markets in advanced stages of clinical development.
Spectrum's strong track record for in-licensing and acquiring
differentiated drugs, and expertise in clinical development have
generated a robust, diversified, and growing pipeline of product
candidates in advanced-stage Phase 2 and Phase 3 studies. More
information on Spectrum is available at www.sppirx.com.
About Servier Canada
Servier Canada was created in 1978 and is the Canadian affiliate
of Groupe Servier. It is the third largest operation for Servier,
and it belongs to the top 20 research-based pharmaceutical
companies in Canada. Servier Canada is currently marketing two
cardiovascular medicines and is expecting two approvals in the
upcoming months. In line with the global strategy, an Oncology
business unit will support this new franchise of products and
contribute to the diversification of the portfolio. More
information is available at www.servier.ca.
About Groupe Servier
Servier is an independent French-based pharmaceutical company
with a strong international presence in 145 countries. It employs
more than 21.000 people. Its development is driven by the pursuit
of innovation in different therapeutic areas. Among others,
Oncology is one of the key priorities of Servier in terms of
R&D with currently eight new molecular entities in clinical
development in breast cancer, lung cancer, other solids tumors and
various types of lymphomas and leukemias. In 2014, the company
recorded a turnover of €4 billion. 28% of this turnover was
reinvested in R&D. More information is available at
www.servier.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.
These statements are based on management's current beliefs and
expectations. These statements include, but are not limited to,
statements that relate to our business and its future, including
certain company milestones, Spectrum's ability to identify,
acquire, develop and commercialize a broad and diverse pipeline of
late-stage clinical and commercial products, leveraging the
expertise of partners and employees around the world to assist us
in the execution of our strategy, and any statements that relate to
the intent, belief, plans or expectations of Spectrum or its
management, or that are not a statement of historical fact. Risks
that could cause actual results to differ include the possibility
that our existing and new drug candidates may not prove safe or
effective, the possibility that our existing and new applications
to the FDA and other regulatory agencies may not receive approval
in a timely manner or at all, the possibility that our existing and
new drug candidates, if approved, may not be more effective, safer
or more cost efficient than competing drugs, the possibility that
our efforts to acquire or in-license and develop additional drug
candidates may fail, our lack of sustained revenue history, our
limited marketing experience, our dependence on third parties for
clinical trials, manufacturing, distribution and quality control
and other risks that are described in further detail in the
Company's reports filed with the Securities and Exchange
Commission. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law.
SPECTRUM PHARMACEUTICALS, INC.®, FUSILEV®, FOLOTYN®, ZEVALIN®,
MARQIBO®, and BELEODAQ® are registered trademarks of Spectrum
Pharmaceuticals, Inc and its affiliates. REDEFINING CANCER CARE™,
EVOMELA™ and the Spectrum Pharmaceuticals logos are trademarks
owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are
the property of their respective owners.
© 2016 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160111005344/en/
Spectrum PharmaceuticalsShiv Kapoor, 702-835-6300Vice
President, Strategic Planning & Investor
RelationsInvestorRelations@sppirx.comorFRANCE Servier
Communication Department+33 1 55 72 60
37presse@servier.frorCANADA media contactNadine
Doucet, +450-978-9700 Ext:
4225nadine.doucet@servier.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Apr 2023 to Apr 2024